1 / 33

PEPTIDE AND SUBUNIT VACCINES

PEPTIDE AND SUBUNIT VACCINES. COURSE CONTENTS. Vaccines- Introduction Vaccines- History Immunological Adjuvants Types DNA Vaccines Viral Vectors Mucosal Vaccines Peptide Vaccines Subunit Vaccines Vaccine Manufacturing Vaccine Safety Issues Animal Testing of Vaccines

ralph
Download Presentation

PEPTIDE AND SUBUNIT VACCINES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PEPTIDE AND SUBUNIT VACCINES

  2. COURSE CONTENTS • Vaccines- Introduction • Vaccines- History • Immunological Adjuvants • Types • DNA Vaccines • Viral Vectors • Mucosal Vaccines • Peptide Vaccines • Subunit Vaccines • Vaccine Manufacturing • Vaccine Safety Issues • Animal Testing of Vaccines • HPV Vaccine- A case study of Vaccine Development

  3. PEPTIDE VACCINES • Peptide Vaccine are formed by using a specific domain of an antigenic protein. • Instead of encoding whole of the protein, only the epitopic region can be added in to the vaccine preparation.

  4. BASIC STEPS IN PEPTIDE VACCINE PREPARATION • Epitope/ target peptide Identification • Linking • Delivery

  5. 1. EPITOPE IDENTIFICATION • Antigen based • or • Antibody based

  6. 1. a. Antigen based identification • Synthetic peptides have been used as powerful tools to identify class II and class I-restricted T cell epitopes by systematic screening in functional assays • MHC-bound peptides eluted directly from tumor material of patients were identified on the basis of their mass and partial sequence by highly sensitive mass spectrometry • Pool sequencing of MHC-eluted peptides has revealed that peptides bind to MHC I via an allele-specific consensus motif of anchor residues • MHC molecules therefore encoded by different gene loci bind their own distinct (sometimes overlapping) family of peptides

  7. Measles virus- epitope identification • Strategy based on peptides of the hemagglutinin (H) and fusion (F) MV neutralizing antibodies are directed against these glycoproteins • Sequential epitopes for both the proteins have been identified that have the inherent property of stimulating either B or T cell epitopes • Two sequential B cell epitopes have been identified on the H protein by screening a panel of neutralizing and protective antibodies against a complete set of overlapping synthetic peptides HA

  8. EPITOPE IDENTIFICATION- CANCER CELLS • Cancer T-cell Epitopes (TCEs) • Cancer vaccines can be based on whole cancer cells*, Tumor Associated Antigens (TAAs) or peptide fragments of TAAs. • Whole cells- difficult to attain • TAA- laborious, expensive and resemble self antigens causing a problem in discrimination. • So, recombinant TAAs appear to be obvious antigens for tumor vaccines. They are: • Most TAAs are not tumor specific • Peptides derived from TAAs are the true antigens recognized by the T cells • Ease of expression as production of TAA peptides in large quantities may serve as a tumor vaccine

  9. CANCER VACCINE-PREPARATION

  10. 1. b. AntiBODY/ PARATOPE based identification • Antigenic Determinants on Abs Fall in 3 Categories:

  11. Idiotypic network

  12. 1. b. AntiBODY/ PARATOPE based identification • The idiotype (Id) i.eidiotypic determinant is associated with the hypervariable region of the antibody (Ab) molecule • It represents the unique antigenic determinant of that Ab • An Ab-1 is defined as an Ab that recognizes a particular antigen e.g a vaccine candidate • The Id on Ab-1 itself can act as an immunogen that can elicit an immune response; the Abs that bind to the Id on Ab-1 are referred to as anti-idiotypic antibodies ( anti-Id) or Ab-2 • The paratope is the site on Ab-1 that binds to a particular antigen; thus the binding site of an anti-paratope antibody is a molecular mimic of the antigen.

  13. ANTI-IDIOTYPIC ANTIBODIES TO CANCER CELLS- an experiment

  14. 2. linker • Organic stretches • Glycans and other sugars

  15. 3. CARRIER MOLECULE • Peptides need to be linked to another molecule to prevent rapid degradation (HAPTEN). • 1. Keyhole limpet hemocyanin (KLH) • an inert carrier protein from a marine gastropos mollusk • 2. Hepatitis B core protein (HBcAg) • highly immunogenic carrier protein which self assembles into small particles

  16. Limitations of Peptide Vaccines • Epitope must consist of a contiguous stretch of amino acids • Not all peptides are effective in eliciting an immune response (may need two or more) • Peptide must have the same conformation as in pathogen • Amount of peptide required to elicit an immune response may be 1000X more than for inactivated pathogen

  17. SUBUNIT VACCINES • Subunit vaccines consist of one or more antigens purified from the microorganism or produced by recombinant DNA technology or chemical synthesis

  18. processing • Development of subunit vaccines requires knowledge of: • Protective antigen(s) • Ability to produce and purify those antigen(s) on large scale • Ability to prove their protective efficacy in appropriate animal models in vivo and/or in vitro assays • Identification of the potential candidates for development of subunit vaccines therefore has to be based on approach combining study of: • Genetics • Biochemistry • Immunology

  19. PROTEIN BASED • The identification of protective antigens is a complex problem and involves approaches that can differ for viruses, bacteria and parasites • Viruses have generally small genomes encoding a few proteins that can easily be selected when compared with larger microorganisms • Envelope proteins and glycoproteins are the primary candidates for the induction of neutralizing antibodies whereas core antigens are usually good candidates for CTL responses • For bacteria and parasites there can be several hundred potential candidate antigens

  20. CARBOHYDRATE BASED • The first subunit vaccines developed have been the diphtheria and tetanus toxoids • Semi-purified toxins are inactivated by chemical (formaldehyde) treatment and used as vaccines • For these two vaccines the titers of serum antitoxin antibodies correlate well with the protection • For encapsulated bacteria the capsular polysaccharide as an antigen was chosen for development of vaccine on the observation that mutants without capsule are non-pathogenic • Meningococcal group specific immunity is mediated by serum antibodies directed against the group-specific capsular polysaccharide.

  21. EXAMPLES • Purified capsular polysaccharides have been used to develop vaccines against • MenC, • N. meningitidis group A (MenA) • N. meningititdis group Y (MenY) • N. meningititdis group MenW135 (MenW135) • Using the polysaccharide, vaccines have been developed against • 23 serotypes of S. pneumoniae • Hib • Salmonella typhi

  22. drawbacks • All these vaccines have several drawbacks • Capsular polysaccharides are T-independent antigens and they induce transient antibody responses (mostly IgM and IgG2 isotypes) in individuals aged over 18 with no efficacy in infants • Polysaccharides do not induce immunological memory • Repeated immunization not only fails to induce any increase in specific antibody titers but can also in some cases even induce tolerance (in adults) • To overcome these drawbacks the toxoids and the polysaccharides have been put together in the form of a conjugate vaccine

  23. conjugation

  24. POSSIBLE SOLUTIONS • During 1920s it was demonstrated that the immunogenicity of saccharides was significantly increased when animals were immunized with the sugarcovalently linked to protein which behaved as carrier molecule • This process converts T-independent antigens into T-dependent antigens • The only limitation of this technology is the overload of carrier protein that patients would receive in the situations where all conjugated vaccines use the same carrier • Carriers not only help the production of anti-oligosaccharide antibodies but also induce specific antibodies against themselves • Anti-carrier antibodies suppress the induction of anti-oligosaccharide antibodies in animals.

  25. Conjugate vaccines • Hib • The first conjugate vaccine developed has been against Hib: • It has a high immunogenicity and efficacy • Induces immunological memory • Igisotype switching • Antibody affinity maturation in children aged less than 18 months • Un-conjugated polysaccharide vaccine fails to induce any of the above responses

  26. Recombinant DNA approach for subunit vaccines • Identification of a relevant antigen can take several years • It is possible that antigens expressed during the infection in vivo are not equally well expressed in vitro during cultivation • Once a suitable antigen is identified most often it is expressed in genetically engineered prokaryotic or eukaryotic vectors • Although this approach has been a success in the case of viruses it has failed up till now for complex pathogens like bacteria and parasites

  27. PARTICLES BASED APPROACH

  28. particles • First application for Hepatitis B through expression of HBsAg gene in bakers yeast i.e S. cerevisae • Notably expression of the HBsAg gene in E.coli gave rise to HBsAg polypeptides but not of HBsAg particles • HBsAg is a virus like particle (VPL) in that its surface structure is similar to that of HBV virion • Purified yeast derived HBsAg is adjuvanted with Aluminum salts for formulation as vaccines • HBsAg has also been expressed in transgenic potato tubers (immunogenic and edible) • HPVvirion is a highly ordered structure with major protein L1 • Expression of L1 in eukaryotic cells results in the formation of VLPs that elicit HPV-neutralizing antibodies leading to protective immunity

  29. Vaccines for non-infectious diseases • Allergy • Oncology • Autoimmunity • Crude extracts from allergens such as ragweed can be used as therapeutic vaccines • Therefore an allergen encoding gene is expressed in a hetrologous host cell • DIABETES • Before the clinical symptoms of the disease develop, autoantibodies become detectable to pancreatic beta cell autoantigense.ginsulin. Following which beta cells are destroyed by autoimmune attack. • A range of recombinant autoantigens can prevent the development of type 1 diabetes in a mouse model • Clinical trials show that subcutaneous injection of E.coli derived recombinant insulin into pre-diabetic patients resulted in a significant delay in development of clinical type 1 diabetes

  30. HOSTS FOR THE EXPRESSION OF RECOMBINANT PROTEINS • Bacteria • E.coli • Bordetellapertusis • Vibrio cholerae • Yeast • S. cerevisiae • Hansenulapolymorpha • Mammalian cells • Chinese hamster ovary • African green monkey kidney • Lymphoid cells • Mammals • Goat • Sheep • Cow • Plants • Tomato • Potato • Tobacco

  31. Failures in the development of subunit vaccines • Among the examples of failures of conventional subunit vaccines are three diseases: • Acquired Immunodeficiency Syndrome • Tuberculosis • Malaria • AIDS • Approaches to vaccine development have essentially focused onto the proteins of the HIV-1 envelope mainly gp120 • Problems: • Antigen variability • Poor ability of these vaccine constructs to induce antibodies that are able to neutralize heterologous viral strains • Effective approach is to aim for inducing both antibody and CTL responses

  32. Failures in the development of subunit vaccines • Tuberculosis • Problems: • Intracellular location of Mycobacterium tuberculosis, which needs the development of Th1-type and MHC class I-restricted CTL responses • Lack of ideal experimental animal models of infection • Malaria • Problems • Immunity against malaria parasites is not only specie specific but also specific for each stage of development • The effector mechanisms required for protection are different for each developmental stage • Ideal malarial vaccine therefore should consist of a mixture of antigens from the different stages of development of the parasite

  33. Thank you

More Related